Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Wades Into the Opioid Debate

This article was originally published in RPM Report

Executive Summary

Reducing prescription drug abuse is a high priority item for several key legislators and for the Obama Administration. Proposed new rules for Medicare drug plan sponsors might help—but they also underscore the growing tension among the many different stakeholders in the pharmaceutical supply chain.

You may also be interested in...

“Messing With Success”: CMS’ Case For Changing Part D – And How Data Sharing May Help

CMS is backing down from some of the more controversial ideas in what would have been a sweeping update to the rules for Part D, after facing broad opposition. However, the bigger message from the proposed rule is that CMS’ isn’t going to stop trying to improve Part D – and one relatively minor provision that is moving forward may recruit more outsiders to that cause.

Class Warfare: CMS Proposes Sweeping Changes to Part D; “Protected Class” Cuts Just the Start

The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.

Part D 2014 Draft Call Letter Addresses Automatic Rx Refills, Drug Safety Issues

CMS instructions to Part D sponsors cite elimination of waste as a reason to require plans to confirm members want a refill. Draft call letter also addresses expanding drug utilization reviews beyond opioids, added controls on compounded drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts